Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «Московский НИИ психиатрии» – филиал ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П.Сербского» Минздрава России. 107076, Россия, Москва, ул. Потешная, д. 3
Список исп. литературыСкрыть список 1. Abbott F., Anari M. Chemistry and biotransformation. Valproate. Ed. by W.Lösher, 1999; p. 47−75. 2. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998; 43: 73−7. 3. Biggs CS, Pearce BR, Fowler LJ et al. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992; 59: 1702–8. 4. Bogan AM, Brown ES, Suppes T. Efficacy of divalproex therapy for schizoaffective disorder. J Clin Psychopharmacol 2000; 20: 520−2. 5. Bowden C, Brugger A, Swann A et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918–24. 6. Сalabrese J, Delucchi G. Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989; 50: 30−4. 7. Calabrese J, Woyshville M, Kimmel S et al. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993; 13: 280−3. 8. Carraz G, Darbon M, Lebreton S et al. Proprietes pharmacodinamiques de l’acide n-dipropylacetique et de ses derives. Therapy 1964; 19; 468−76. 9. Clark RD, Canive JM, Calais LA et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999; 12: 395−401. 10. Davis LL, Kabel D, Patel D et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996; 32: 647–52. 11. DelBello MP, Lopez-Larson MP, Getz GE et al. Treatment of schizoaffective disorder with divalproex sodium. Schizophr Res 2000; 46: 77−9. 12. Donovan SJ, Susser ES, Nunes EV et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 1997; 58: 12−5. 13. Emrich H, von Zerssen D, Kissling W et al. Effect of sodium valproate in mania. The GABA hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980; Bd. 229: 1−16. 14. Förstl H. Neurodegenerative und verwandte Erkrankungen. Frontalhirn. Funktionen und Erkrankungen. 2 Auflage. Berlin: Springer Medizin Verlag, 2005; s. 144−75. 15. Fountain N, Dreifuss F. The future of valproate. Valproate. Ed. by W.Lösher, 1999; p. 265−76. 16. Gualtieri CT. Neuropsychiatry and behavioral pharmacology. Berlin: Springer-Verlag, 1991. 17. Hirsch E, Schmitz B, Carreňo M. Epilepsy, antiepileptic drugs (AEDs) and cognition. Acta Neurologica Scand 2003; 108 (Suppl. 180): 23−32. 18. Hollander E, Allen A, Lopez RP et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62: 199−203. 19. Hooper W, Franklin M, Glue P et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of b-oxidation. Epilepsia 1996; 37: 91–7. 20. Ichikawa J, Meltzer HY. Valproate and carbamazepine increase prefront al dopamine release by 5-HT1A receptor activation. Eur J Pharmacol 1999; 380: R1−R3. 21. Janz D. "Auchwach"-epilepsien (als ausdruck einer den "nacht" oder "schlaf"-epilepsien gegenuberstehenden verlaufsform epileptischer erkrankungen. Arch Psychiat Nervenkr 1953; Bd. 191: 73−98. 22. Kalinin VV. Suicidality and antiepileptic drugs. Is there a link? Drug Safety 2007; 30 (2): 123–42. 23. Kalinin V, Polyanskiy D. Gender differences in risk factors of suicidal behavior in epilepsy. Epilepsy Behav 2005; 6 (3): 424−9. 24. Kalinin V, Polyanskiy D. Gender and suicidality prediction in epilepsy. Epilepsy Behav 2005; 7 (4): 657−63. 25. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59: 676−80. 26. Keck P, Taylor V, Tugrul K et al. Valproate treatment of panic disorders and lactate-induced panic attacks. Biol Psychiatry 1993; 33: 542–6. 27. Kemp LI. Sodium valproate as an antidepressant. Br J Psychiatry 1992; 160: 121−3. 28. Ketter T, Post R, Theodore W. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53 (Suppl. 2): S53−S67. 29. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000; 61: 123–8. 30. Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976; 129: 114–9. 31. Lösher W. Pharmacological effects and mechanisms of action. Valproate. Ed. by W.Lösher. Basel: Birkhäuser Verlag, 1999; p. 7–45. 32. Lösher W. The discovery of valproate. Valproate. Ed. by W.Lösher, 1999; p. 1−3. 33. Lösher W. Valproic acid. Mechanisms of action. In: Antiepileptic Drugs, fifth edition Ed. by R.Levy, R.Mattson, B.Meldrun, E.Perucca. Philadelphia: LWW, 2002; p. 767–79. 34 Marneros A. Das Neue Handbuch der Bipolaren und Depressiven Erkrankungen. Georg Thieme Verlag 2004; 781. 35. Meunier H, Carraz G, Meunier Y et al. Propriétés pharmacodinamiques de l’acide n-dipropylacetique. 1er memoire: Propriétés antiepileptiques. Thérapie 1963; 18: 435–8. 36. Miller CH, Fleischhacker WW. Neurologische Neuroleptika-Nebenwirkungen. Klinische Neuro-Psychiatrie. Neurologie psychischer Störungen Psychiatrie neurologischer Erkrankungen. Stuttgart: Thieme Verlag, 2000; S. 449−78. 37. Nair NP, Lal S, Schwartz G et al. Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies. Adv Biochem Psychopharmacol 1980; 24: 437−41. 38. Niedermier JA, Nasrallah HA. Clinical correlates of response to valproate in geriatric inpatients. Ann Clin Psychiatry 1998; 10: 165−8. 39. Pies R, Adler DA, Ehrenberg BL. Sleep disorders and depression with atypical features: response to valproate. J Clin Psychopharmacol 1989; 9: 352−7. 40. Post R. Valproate use in psychiatry: a focus on bipolar illness. Valproate. Ed. by W.Lösher, 1999; p. 167–201. 41. Schmidt D. Adverse effects and interactions with other drugs. Valproate. Ed. by W.Lösher, 1999; p. 224–64. 42. Swann AC. Valproic acid. Clinical efficacy and use in psychiatric disorders. In: Antiepileptic Drugs, 5th edition. Ed. by R.Levy, R.Mattson, B.Meldrun, E.Perucca. Philadelphia: LWW, 2002; p. 828−36. 43. Wassef AA, Dott SG, Harris A et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment acute exacerbations of chronic schizophrenia. J Clin Psychopharnacol 2000; 20: 357−61. 44. Wassef AA, Hafiz NG, Hampton D et al. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001; 21: 21−6. 45. Wetterling T. Organische psychische Störungen. Hirnorganische Psychosyndrome. Darmstadt: Steinkopff Verlag, 2002. 46. Whitton PS, Oreskovic D, Jernej B et al. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain. J Pharm Pharmacol 1985; 37: 199–200. 47. Winsberg M, Degolia S, Strong C et al. Divalproex in medication naïve bipolar II depression. APA New Research Program and Abstracts 1997; Abstr. NR113: 97. 48. Yuen A, Land G, Weatherley B et al. Sodium valproate acutely inhibits lamotrigene metabolism. Brit J Clin Pharmacol 1992; 33: 511−3. 49. Zimmer R, Teelken AW, Gūndūrewa M et al. Effect of sodium valproate on CSF GABA, cAMP, cGMP and homovanillic acid levels in men. Brain Res Bull 1980; 5 (Suppl. 2): 585−8.